Drug Trial Radar · NCT06636500
A Phase 1 Study of CG001419 Administered Orally in Healthy Subjects
Last checked: Nov 20, 2026Latest source record: Feb 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
72
Actual
Start
Jan 22, 2025
Primary completion
Dec 5, 2025
Study completion Dec 5, 2025
Sponsor
- Lead sponsor
- Cullgen Australia Pty LtdIndustry
- Sponsor type
- Industry
- First posted
- Oct 10, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a dose finding study of CG001419, administered as a single dose, with or without food, and as multiple doses. CG001419 is being tested in healthy volunteers in this trial with the goal of eventually developing the drug for patients with pain if it is found to be safe and well tolerated.
Conditions
- Healthy Volunteer Study
- Pain Management
Interventions
CG001419Drug
Oral doses
PlaceboDrug
Oral doses
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the safety and tolerability of single and multiple ascending oral doses of CG001419 in healthy subjectsTime frame: Up to 7 days of dosing
Locations
1 site in 1 country. Site status is shown where the registry gives one.
CMAX Clinical Research
Adelaide, South Australia, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.